Preferred Label : Anti-BCMA/Anti-GPRC5D CAR-T Cells OriC321;
NCIt synonyms : Bispecific BCMA/GPRC5D-targeted CAR T Cells OriC321; BCMA/GPRC5D Dual Target CAR-T Cells OriC321; BCMA/GPRC5D-targeted CAR T-cells OriC321;
NCIt definition : A preparation of T-lymphocytes engineered to express chimeric antigen receptor(s)
(CAR) targeting the human tumor-associated antigens (TAAs) B-cell maturation antigen
(BCMA; tumor necrosis factor receptor superfamily member 17; TNFRSF17) and G-protein
coupled receptor family C group 5 member D (GPRC5D) and fused to as of yet not fully
elucidated co-stimulatory domains, with potential immunostimulating and antineoplastic
activities. Upon administration, the anti-BCMA/anti-GPRC5D CAR-T cells OriC321 specifically
and simultaneously target and bind to tumor cells expressing BCMA and/or GPRC5D. This
induces selective toxicity in tumor cells that express BCMA and/or GPRC5D. BCMA, a
receptor for both a proliferation-inducing ligand (APRIL) and B-cell activating factor
(BAFF), is a member of the tumor necrosis factor receptor superfamily (TNFRSF). BCMA
is found on the surfaces of plasma cells, is overexpressed on malignant plasma cells
and plays a key role in plasma cell proliferation and survival. GPRC5D is overexpressed
in certain malignancies, such as multiple myeloma, while minimally expressed in normal,
healthy cells. It plays a key role in tumor cell proliferation.;
Molecule name : OriC-321; OriC 321;
NCI Metathesaurus CUI : CL1792005;
Origin ID : C187125;
UMLS CUI : C5706372;
Semantic type(s)
- Cell [UMLS semantic type]
- concept_is_in_subset
- has_target
